Bill > AB382

This bill expands the requirements for health insurance coverage of biomarker testing across multiple types of health plans in Nevada, including private insurers, Medicaid, and plans for state and local employees. Previously, these plans were only required to cover biomarker testing that was medically necessary and specifically for cancer diagnosis and treatment. The new legislation removes these limitations, mandating that health plans cover biomarker testing for any medical condition or disease when such testing is supported by medical and scientific evidence. The bill defines biomarker testing broadly, including single-analyte tests, multiplex panel tests, and even whole genome sequencing. Health plans must now provide a clear process for requesting exceptions or appealing denials of biomarker testing coverage, and must respond to prior authorization requests within 24 hours for urgent requests and 72 hours for other requests. The coverage requirements will apply to health plans delivered, issued, or renewed on or after January 1, 2026. The bill still allows health plans to deny coverage for biomarker testing conducted outside a provider's scope of practice or by providers/facilities outside their network, but removes the previous requirement that testing be deemed "medically necessary" by a healthcare provider.

Business and Industry

https://www.leg.state.nv.us/App/NELIS/REL/83rd2025/Bill/12526/Overview